2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Biological Therapies, Chimeric Antigen Receptor, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Genetic Disorders, Immunology, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Metabolic Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1375 Phip contributes to hematopoietic stem cell aging and shares PHF6-associated dependencies in T-cell leukemia

Laura Quevedo, PhD, Anqi Wang, PhD2, Hannah Miller3, Mayukh Biswas4, Ryan D. Najac5, Aidan S. Quinn6, Cindy Ma7, Kalay Bertulfo, PhD8, Anouchka P. Laurent, PhD9, Ruth Alonso Alonso, PhD10, Wen-Hsuan Wendy Lin, MD, PhD11, Raul Rabadan, PhD12, Adolfo Ferrando13, Silvia Alvarez, PhD14, Teresa Palomero15
1 Columbia University Irving Medical Center, New York, New York, United States
2 Columbia University Medical Center, New York, New York, United States
3 Columbia University Irving Medical Center, New York, New York, United States
4 Presidency University, Kolkata, India
5 Columbia University Irving Medical Center, New York, New York, United States
6 Columbia University Irving Medical Center, New York, New York, United States
7 Columbia University Irving Medical Center, New York, New York, United States
8 Columbia University Irving Medical Center, New York, New York, United States
9 Columbia University Irving Medical Center, New York, New York, United States
10 Columbia University Irving Medical Center, New York, New York, United States
11 Duke University School of Medicine, Durham, North Carolina, United States
12 Columbia University Medical Center, New York, New York, United States
13 Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States, Regeneron Pharmaceuticals, Tarrytown, New York, United States
14 Columbia University Irving Medical Center, New York, New York, United States, Regeneron Pharmaceuticals, Tarrytown, New York, United States
15 Columbia University Irving Medical Center, New York, New York, United States, Columbia University Irving Medical Center, New York, New York, United States
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy that, despite improved outcomes with intensified chemotherapy, remains associated with substantial treatment-related toxicity and poor survival in the relapsed/refractory setting. T-ALL arises through the accumulation of genetic and epigenetic alterations that disrupt normal hematopoietic development. PHF6 is a chromatin regulator and tumor suppressor frequently mutated in T-ALL. Work from our group has shown that PHF6 is an important regulator of hematopoietic stem cell (HSC) aging and that its loss in murine models rejuvenates HSCs. More recently, our group and others identified PHIP as a PHF6-interacting protein, a relationship studied predominantly in the context of myeloid leukemias. However, the contribution of PHIP to HSC biology and to T-ALL pathogenesis remains unexplored.
To investigate PHIP function in vivo, we generated a hematopoietic-specific conditional Phip knockout (KO) mouse model. Competitive transplantation assays revealed that PHIP loss confers a sustained competitive repopulation advantage, with increased long-term donor contribution across multiple hematopoietic lineages, indicating that PHIP-deficient HSCs retained multilineage differentiation capacity.
We next examined the impact of PHIP loss on age-associated hematopoietic remodeling. Immunophenotypic analysis of young and aged mice revealed that PHIP deficiency attenuates the characteristic age-associated expansion of LT-HSCs observed in wild-type animals. Aged Phip-KO mice exhibited reduced LT-HSC accumulation, preservation of myeloid-biased progenitors (MPP2/3) and lymphoid-primed MPP4 populations, and decreased expression of aging- and exhaustion-associated surface markers. These phenotypes closely resembled those previously reported in aged Phf6-deficient mice but were quantitatively milder, suggesting a hypomorphic yet functionally aligned role for PHIP in regulating HSC aging.
To define the transcriptional basis of these phenotypes, we performed single-cell RNA sequencing of LSK cells isolated from young and aged wild-type and Phip-KO mice. PHIP loss selectively limited the expansion of transcriptionally exhausted HSC states in aged mice while preserving overall HSC identity. Comparative analysis of the Phip data with our published Phf6 single-cell datasets processed through a unified pipeline, uncovered highly concordant transcriptional trajectories, including suppression of an aging-associated HSC gene signature. Pathway enrichment analysis identified shared activation of immune-, cytokine-, and interferon-associated programs, alongside distinct transcriptional changes uniquely regulated by PHIP or PHF6 loss.
To investigate the role of PHIP in T-ALL, we generated CRISPR-mediated PHIP and PHF6 knockout models in Jurkat and PF382 T-ALL cell lines. Under standard culture conditions, loss of either PHIP or PHF6 had no major effects on cell viability or apoptosis, indicating that neither gene is essential for leukemic cell viability. To define transcriptional changes induced by PHIP or PHF6 loss, we performed bulk RNA sequencing. Transcriptomic analysis revealed overlapping transcriptional programs affected by PHIP and PHF6 loss, including downregulation of the p53 pathway and components of the unfolded protein response, suggesting convergence on shared stress-response and metabolic pathways.
Finally, to define genetic dependencies associated with PHIP or PHF6 loss that could be relevant for our understanding of the role of these tumor suppressors in T-cell leukemia, we performed genome-wide CRISPR knockout screens in PF382 cells lacking PHIP or PHF6. Comparative analysis demonstrated highly correlated genetic dependency profiles between PHIP- and PHF6-deficient cells, with shared vulnerabilities significantly enriched for chromatin regulatory factors and DNA damage response pathways. Together, these results indicate that loss of PHIP recapitulates core PHF6-dependent genetic dependencies in leukemic cells, supporting functional convergence between these chromatin-associated regulators in leukemia-relevant contexts.
In summary, these data identify PHIP as a regulator of stem cell fitness, aging-associated exhaustion, and T-cell leukemia-specific genetic dependencies.
Laura Quevedo, PhD: No relevant conflicts of interest to declare.